Clinical Trial Detail

NCT ID NCT02478320
Title Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

Advanced Solid Tumor

Therapies

ABT-348

Age Groups: adult senior

Additional content available in CKB BOOST